Theia Pharma: A commitment to innovation and ophthalmology
Theia Pharma applies the most stringent FDA standards to formulate TMoxiOG™ and our topical formulations, preparing for FDA approval while satisfying the 503b surgical end-user, a meticulous process that redefines compounding excellence.
Creating innovative ophthalmic formulations for eye doctors
Our comprehensive suite of preservative-free ophthalmic medications caters to the diverse preferences of eye surgeons and optometrists, ranging from injectable prophylaxis after cataract surgery to potent preservative-free steroid-antibiotic combination eye drops.
Seeking FDA Approval: TMoxiOG
Pursuing a drop-free solution with cataract surgery is a universal goal for surgeons.
Serving the USA Market First
503b manufacturing with the quality assurance process to satisfy FDA 505b2 approval
Introducing Topical DuraMoxi™
Difluprednate, the active ingredient in Durezol™, combined with Moxifloxacin
Global Patent Protection
The only combination formulation patented in Europe, North America, South America, and Asia
Rapidly Growing Surgical Market
10% of the 3.5M cataracts (USA) annually. Once FDA approved: 60% with ASC reimbursement
International Sales Planned
FDA approval of TMoxiOG will be followed by International approvals: 85M cataracts annually
503b Production CDMO Manufacturing
Best cGMP manufacturing to FDA standards for approved medications, highest quality and safety, rigorous validation and surveillance
TMoxiOG™ Injectable
- ASC/HOPD Vials (0.6ml)
- Bulk Purchases in boxes of 20
- Just in Time Delivery Promise
- Once FDA Approved: Reimbursable
DuraMoxi™ Topical
- Potent steroid; 4th Generation Antibiotic
- Twice a day (BID) Suppression Dosing
- Preservative-Free, No Irritation
- Nano-Size Particles: No Clumping
“TMoxiOG™ has been used in nearly two million eyes with excellent prophylaxis results, saving patients with perfect compliance and incredible convenience.”
Jeffrey Liegner, MD
CEO, Theia Pharma
Watch, Read, Listen, Share, Blog
-
Hello Eye Surgeons and Optometrists! Ask for the OG for the patient’s benefit.
Your patients deserve the original triamcinolone-moxifloxacin formulation with a patented formulation, preparing to seek FDA approval, followed by J-Code assignment, leading to ASC/HOPD reimbursement by insurance and Medicare, saving our US Government (Medicare Part D) over $7B in the first decade.
—
by
Join 900+ eye surgeons having used TMoxiOG™
Stay in the loop with drop-free surgical prophylaxis.